|
Re: ACC 2019 Abstracts
|
3
|
Resverlogix Corp.
|
Mar 04, 2019 03:40PM
|
|
Re: eGFR data question from IR
|
3
|
Resverlogix Corp.
|
Nov 26, 2019 05:20PM
|
|
Re: MACE Event rate,....
|
3
|
Resverlogix Corp.
|
Mar 01, 2019 05:05PM
|
|
Re: Reata, Bardoxolone, NRF2, CKD, Mitochondria, Inflammation, Redox Balance, Reactive Oxygen Species
|
3
|
Resverlogix Corp.
|
Jun 14, 2019 11:23AM
|
|
Re: A hunch about the below median LDL-C observation
|
3
|
Resverlogix Corp.
|
Nov 20, 2019 03:31PM
|
|
Re: EDITRe: i would love to hear,..
|
3
|
Resverlogix Corp.
|
Dec 06, 2019 04:52PM
|
|
Re: A hunch about the below median LDL-C observation
|
3
|
Resverlogix Corp.
|
Nov 20, 2019 03:44PM
|
|
Re: ACC 2019 Abstracts
|
3
|
Resverlogix Corp.
|
Mar 04, 2019 11:04PM
|
|
Re: Question to ask at the AGM
|
3
|
Resverlogix Corp.
|
Oct 31, 2019 01:35PM
|
|
Re: BRD2 involvement in Covid19
|
3
|
Resverlogix Corp.
|
Mar 18, 2020 12:40PM
|
|
Re: RVX-297 vs RVX-208 for autoimmune indications
|
3
|
Resverlogix Corp.
|
Jan 09, 2019 01:07PM
|
|
Re: BRD2 involvement in Covid19
|
3
|
Resverlogix Corp.
|
Mar 18, 2020 01:10PM
|
|
Re: Angiotensin and Coronavirus
|
3
|
Resverlogix Corp.
|
Mar 23, 2020 10:20PM
|
|
Re: RVX-297 vs RVX-208 for autoimmune indications
|
4
|
Resverlogix Corp.
|
Jan 09, 2019 04:00PM
|
|
Re: BD2 specific inhibitors mentioned in Science
|
4
|
Resverlogix Corp.
|
Mar 22, 2020 01:46PM
|
|
Re: What we know and what we don't.....
|
4
|
Resverlogix Corp.
|
May 16, 2019 05:00PM
|
|
orphan diseases
|
4
|
Resverlogix Corp.
|
Jun 30, 2018 10:57PM
|
|
Re: ACC 2019 Abstracts
|
4
|
Resverlogix Corp.
|
Mar 19, 2019 02:36PM
|
|
Re: balancing success and failure
|
4
|
Resverlogix Corp.
|
Nov 19, 2019 08:59PM
|
|
Re: ACC 2019 Abstracts
|
4
|
Resverlogix Corp.
|
Mar 19, 2019 03:24PM
|
